| References: |
Murepavadin is a pathogen specific antimicrobial peptidomimetic with a novel, non-lytic mechanism of action, and is the first in class of outer membrane protein targeting antibiotics which are being developed. Murepavadin displays a potent in vitro activity including carbapenemase-producing and colistin-resistant P. aeruginosa. Murepavadin is active in pre-clinical animal models including infections with XDR isolates. The Pharmacokinetics is well characterized including subjects with impaired renal function and patients with VABP. Intravenous murepavadin is currently under clinical development for the treatment of HABP/VABP due to P. aeruginosa infection.Murepavadin, a pathogen-specific antibiotic, is being developed for hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP) caused by Pseudomonas aeruginosa.Murepavadin fits well with the new trend in antibiotic use known as ‘antibiotic stewardship’ which, among other things, aims to reduce the excessive use of broad-spectrum products which generates resistance.Murepavadin has obtained QIDP (Qualified Infectious Disease Product) status and eligibility for priority review, with statutory exclusivity for an additional five years upon FDA approval. |
